The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.
We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.
Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.
As of today (2024-04-24), Nektar Therapeutics's share price is $1.42. Nektar Therapeutics's GF Value is $2.99. Therefore, Nektar Therapeutics's Price-to-GF-Value for today is 0.47.
Based on the relationship between the current stock price and the GF Value, GuruFocus believes Nektar Therapeutics is Possible Value Trap, Think Twice.
Nektar Therapeutics (NAS:NKTR) GF Value Explanation
Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:
(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.
(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.
(3) There is only a sufficient margin of safety when the stock is undervalued.
Nektar Therapeutics's Price-to-GF-Value for today is calculated as
Price-to-GF-Value
=
Share Price
/
GF Value
=
1.42
/
2.99
=
0.47
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nektar Therapeutics GF Value Related Terms
Thank you for viewing the detailed overview of Nektar Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Nektar Therapeutics (Nektar Therapeutics) Business Description
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NKTR has been successfully added to your